Nuvation Bio (NUVB) Assets Average (2020 - 2026)
Nuvation Bio (NUVB) posted quarterly Assets Average of $602.5 million for Q1 2026, up 16.64% year-over-year from $516.6 million in Q1 2025, and up 0.73% quarter-over-quarter from $598.2 million in Q4 2025.
Nuvation Bio (NUVB) Assets Average (2020 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Assets Average for 7 consecutive years, with $602.5 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 16.64% year-over-year to $602.5 million; the TTM figure through Mar 2026 stood at $602.5 million (up 16.64% YoY), while the FY2025 annual figure was $567.7 million, down 2.29% from the prior year.
- Assets Average improved to $602.5 million in Q1 2026 per NUVB's latest filing, from $598.2 million in the prior quarter.
- Across five years, Assets Average topped out at $764.0 million in Q1 2022 and bottomed at $516.6 million in Q1 2025.
- Historically, Assets Average has averaged $631.2 million across 5 years, with a median of $624.4 million in 2025.
- Annual changes were most pronounced in 2022 — Assets Average surged 44.99% — and 2025, when it retreated 16.32%.
- Nuvation Bio's Assets Average stood at $679.3 million in 2022, then slipped by 7.82% to $626.2 million in 2023, then retreated by 11.19% to $556.1 million in 2024, then advanced by 7.57% to $598.2 million in 2025, then grew by 0.73% to $602.5 million in 2026.
- Business Quant data shows NUVB's Assets Average at $602.5 million in Q1 2026, $598.2 million in Q4 2025, and $624.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn | 677.37 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 677.37 Mn |
| Mar 31, 2026 | 602.53 Mn |
| Dec 31, 2025 | 598.19 Mn |
| Sep 30, 2025 | 624.39 Mn |
| Jun 30, 2025 | 569.86 Mn |
| Mar 31, 2025 | 516.56 Mn |
| Dec 31, 2024 | 556.10 Mn |
| Sep 30, 2024 | 583.19 Mn |
| Jun 30, 2024 | 603.96 Mn |
| Mar 31, 2024 | 617.30 Mn |
| Dec 31, 2023 | 626.18 Mn |
| Sep 30, 2023 | 636.14 Mn |
| Jun 30, 2023 | 649.23 Mn |
| Mar 31, 2023 | 664.60 Mn |
| Dec 31, 2022 | 679.32 Mn |
| Sep 30, 2022 | 703.11 Mn |
| Jun 30, 2022 | 735.77 Mn |
| Mar 31, 2022 | 763.98 Mn |
| Dec 31, 2021 | 786.97 Mn |
| Sep 30, 2021 | 806.03 Mn |